These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21360612)

  • 1. Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation.
    Park IH; Li C
    J Mol Recognit; 2011; 24(2):254-65. PubMed ID: 21360612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening.
    Hao W; Hu Y; Niu C; Huang X; Chang CP; Gibbons J; Xu J
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4988-92. PubMed ID: 18768317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of potent STAT3-SH2 domain inhibitors from JAK/STAT compound library through molecular dynamics simulation.
    Manoharan S; Balakrishnan A; Hemamalini V; Perumal E
    Mol Divers; 2023 Jun; 27(3):1297-1308. PubMed ID: 35831728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity.
    Dourlat J; Liu WQ; Sancier F; Edmonds T; Pamonsinlapatham P; Cruzalegui F; Garbay C
    Biochimie; 2009 Aug; 91(8):996-1002. PubMed ID: 19470402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of phosphotyrosine recognition by the SH2 domain of the Src kinase.
    Bradshaw JM; Mitaxov V; Waksman G
    J Mol Biol; 1999 Nov; 293(4):971-85. PubMed ID: 10543978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for the binding of high affinity phosphopeptides to Stat3.
    McMurray JS
    Biopolymers; 2008; 90(1):69-79. PubMed ID: 18058821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel high-throughput screening system for identifying STAT3-SH2 antagonists.
    Uehara Y; Mochizuki M; Matsuno K; Haino T; Asai A
    Biochem Biophys Res Commun; 2009 Mar; 380(3):627-31. PubMed ID: 19285012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization.
    Resetca D; Haftchenary S; Gunning PT; Wilson DJ
    J Biol Chem; 2014 Nov; 289(47):32538-47. PubMed ID: 25288792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor.
    Coleman DR; Ren Z; Mandal PK; Cameron AG; Dyer GA; Muranjan S; Campbell M; Chen X; McMurray JS
    J Med Chem; 2005 Oct; 48(21):6661-70. PubMed ID: 16220982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New syntheses of tetrazolylmethylphenylalanine and O-malonyltyrosine as pTyr mimetics for the design of STAT3 dimerization inhibitors.
    Dourlat J; Valentin B; Liu WQ; Garbay C
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3943-6. PubMed ID: 17509878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational investigation of the specificity determining region of the Src SH2 domain.
    Bradshaw JM; Mitaxov V; Waksman G
    J Mol Biol; 2000 Jun; 299(2):521-35. PubMed ID: 10860756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CH/pi hydrogen bonds determine the selectivity of the Src homology 2 domain to tyrosine phosphotyrosyl peptides: an ab initio fragment molecular orbital study.
    Ozawa T; Okazaki K
    J Comput Chem; 2008 Dec; 29(16):2656-66. PubMed ID: 18484636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
    Lange G; Lesuisse D; Deprez P; Schoot B; Loenze P; Bénard D; Marquette JP; Broto P; Sarubbi E; Mandine E
    J Med Chem; 2003 Nov; 46(24):5184-95. PubMed ID: 14613321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of solvation sites at the interface of Src SH2 domain complexes using molecular dynamics simulations.
    Geroult S; Hooda M; Virdee S; Waksman G
    Chem Biol Drug Des; 2007 Aug; 70(2):87-99. PubMed ID: 17683370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding.
    Nam NH; Ye G; Sun G; Parang K
    J Med Chem; 2004 Jun; 47(12):3131-41. PubMed ID: 15163193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding modes of peptidomimetics designed to inhibit STAT3.
    Dhanik A; McMurray JS; Kavraki LE
    PLoS One; 2012; 7(12):e51603. PubMed ID: 23251591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.
    Szelag M; Sikorski K; Czerwoniec A; Szatkowska K; Wesoly J; Bluyssen HA
    Eur J Pharmacol; 2013 Nov; 720(1-3):38-48. PubMed ID: 24211327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains.
    Gunning PT; Katt WP; Glenn M; Siddiquee K; Kim JS; Jove R; Sebti SM; Turkson J; Hamilton AD
    Bioorg Med Chem Lett; 2007 Apr; 17(7):1875-8. PubMed ID: 17336521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands.
    Yao ZJ; King CR; Cao T; Kelley J; Milne GW; Voigt JH; Burke TR
    J Med Chem; 1999 Jan; 42(1):25-35. PubMed ID: 9888830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.
    Yu W; Xiao H; Lin J; Li C
    J Med Chem; 2013 Jun; 56(11):4402-12. PubMed ID: 23651330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.